Ovensa is a preclinical stage company developing the only siRNA drug candidate silencing the overexpression of galectin-1 in cancer. It has shown to improve therapeutic outcomes of checkpoint inhibitors and chemotherapy in recurrent glioblastoma.

Ovensa has entered into R&D collaborations with Takeda and other pharmaceutical companies for using its non-viral and non-lipid TRIOZAN™ Nanomedicine Platform for targeted and BBB-crossing drug delivery.

Ovensa Logo



Event details

Date: June 8 - 12, 2020

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences


34 in total